Introduction {#sec1-1}
============

Psoriasis is a common chronic inflammatory skin disease and is primarily characterized by localized or generalized scaly erythematous plaques. The rapid proliferation of epidermal keratinocytes in the basal layer is the primary pathological characteristic of psoriasis.\[[@ref1]\] Psoriasis is a disease of the immune system. Not only it can affect the skin and joints, but it is also associated with metabolic syndrome, obesity, cardiovascular disease, and mental diseases.\[[@ref2][@ref3][@ref4]\] Furthermore, psoriasis can result in bodily harm to the patient as well as impacts patients' appearance, social activities, and quality of life.

The worldwide prevalence of psoriasis varies in different countries, ranging from 0.6% to 4.8%.\[[@ref5]\] Europe and the United States have higher prevalence at approximately 1%--3%, whereas Asia has the lowest prevalence at approximately 0.3%. Psoriasis can develop at any age, but incidence peaks between 15 and 30 years of age. There is no significant difference in psoriasis incidence between men and women.\[[@ref5]\] Individuals with a family history of psoriasis are more likely to develop psoriasis.\[[@ref6]\]

The pathogenesis of psoriasis is not fully understood. At present, psoriasis is considered as an immune-mediated, polygenic, and genetic disease. A number of environmental factors can trigger or worsen psoriasis such as infection, drugs, stress, trauma, obesity, alcohol consumption, and smoking.\[[@ref7]\]

Copper (Cu) and zinc (Zn) are essential trace elements. The balance of trace elements plays an important role in maintaining overall health. Numerous studies have shown that abnormal serum Cu and Zn levels are important mechanisms underlying the occurrence and development of skin diseases. Cu and Zn deficiencies reduce the activity of enzymes related to melanin synthesis, thereby causing a reduction in melanin production and aggravating white spots or patches of vitiligo.\[[@ref8]\] Cu and Zn abnormalities are also involved in the pathophysiology of psoriasis.\[[@ref9]\] Serum Cu binds to α2 globulin and promotes the formation of ceruloplasmin protein, which is involved in the clearance of excessive free radicals in patients with psoriasis.\[[@ref10]\] Zn serves as a coenzyme for DNA and RNA polymerases and plays an important role in excessive keratinocyte proliferation in psoriatic lesional skin.\[[@ref11]\] Studies have reported that serum Cu levels were increased in patients with psoriasis,\[[@ref12][@ref13][@ref14]\] whereas serum Zn levels were decreased.\[[@ref5][@ref15]\] However, these results have been inconsistent.\[[@ref16][@ref17][@ref18]\] Given the inconsistency of the existing literature and the insufficient statistical power of primary studies, we conducted a meta-analysis to investigate changes in serum Cu and Zn levels in patients with psoriasis.

Materials and Methods {#sec1-2}
=====================
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### Data sources {#sec3-1}

We searched PubMed, Cochrane Central, OVID, SpringerLink, Clinical Evidence, Google scholar, the Chinese National Knowledge Infrastructure, Wanfang Med Online, Chinese Biology Medical Literature Database, and VIP Database for articles published between 1988 and May 2016 in Chinese or English. The search words included psoriasis or skin disease, trace elements, copper, and zinc. References of the included studies were retrieved to identify additional relevant articles.

### Inclusion criteria {#sec3-2}

Studies were included in the meta-analysis if they met the following criteria: studies reported data on patients with psoriasis; studies used a case-control or cohort design; serum Cu or Zn levels were detected; and the sample size, mean, and standard deviation were presented in the results. If there were duplicates or overlapping publications, the first study was included.

### Data extraction {#sec3-3}

Two investigators independently extracted relevant data from the included studies, including the first author name, publication year, country, sample size, and serum Cu or Zn level means and SD values. Any discrepancies in data extraction between the two investigators were resolved by consensus with a third investigator or by re-evaluation of the data from the studies.

### Statistical analysis {#sec3-4}

Data were analyzed with Review Manager 5.3 software (Cochrane Collaboration, Oxford, England). The standardized mean difference (SMD) and 95% confidence intervals (CI) were calculated based on the fixed-effects models or random-effects model. The inconsistency index (I^2^) test was also calculated to measure the inconsistency across studies. When I^2^ \<50%, a fixed-effect model was used to calculate the combined effect value. When I^2^ \>50%, a random-effects model was applied. The significance of combined SMD was assessed by Z test, and *P* \< 0.05 was considered statistically significant. The Begg and Egger tests were used to evaluate the possible existence of publication bias, with *P* \> 0.05 indicative of no publication bias. Influence analysis was used to analyze the impact of the signal study on the overall results of meta-analysis. The Begg test, Egger test, and influence analysis were performed using Stata version 12.0 software. When the mean serum Cu or Zn levels and SD values were not calculated in the included study, but the outcomes in several subgroups were analyzed, the means and SD values across several subgroups were combined and included in the final analysis.

Results {#sec1-3}
=======
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### Results of literature retrieval {#sec3-5}

According to the retrieval strategy, 3874 references were primarily screened, and 15 studies that met the inclusion criteria were ultimately included. A flow chart of the screening is displayed in [Figure 1](#F1){ref-type="fig"}. The characteristics of the included studies are indicated in [Table 1](#T1){ref-type="table"}.

![Flow chart of study selection in the meta-analysis](IJD-64-224-g001){#F1}

###### 

The characteristics of included studies in the meta-analysis

  First author              Year   Location   Total Cases (*n*)   Psoriasis Group (*n*)   Healthy Group (*n*)   Detected in serum       
  ------------------------- ------ ---------- ------------------- ----------------------- --------------------- ------------------- --- ---
  Sheikh G\[[@ref5]\]       2015   India      200                 100                     100                                           √
  Ala S\[[@ref14]\]         2013   Iran       50                  25                      25                                            √
  Afridi HI\[[@ref15]\]     2011   Pakistan   659                 418                     241                                       √   
  Rashmi R\[[@ref19]\]      2010   India      127                 82                      45                    √                       
  Basavaraj KH\[[@ref9]\]   2009   India      75                  50                      25                                            √
  Lei TB\[[@ref20]\]        2008   China      150                 120                     30                                        √   
  Cao JQ\[[@ref21]\]        2005   China      114                 84                      30                                            √
  Nigam PK\[[@ref12]\]      2005   India      80                  60                      20                                            √
  Wang GZ\[[@ref11]\]       2004   China      98                  52                      46                                        √   
  Yan ZD\[[@ref17]\]        2004   China      270                 120                     150                                           √
  Ding ZY\[[@ref18]\]       2003   China      64                  32                      32                                            √
  Halevy S\[[@ref16]\]      2001   Israel     36                  23                      13                                            √
  Tasaki M\[[@ref13]\]      1993   Japan      76                  28                      48                                            √
  Yang WL\[[@ref10]\]       1993   China      90                  70                      20                    √                       
  Doğan P\[[@ref22]\]       1989   Turkey     93                  60                      33                    √                       

Symbol of "√" means the Cu or Zn was studied in the serum

### Changes in serum Cu levels in patients with psoriasis {#sec3-6}

Twelve studies analyzed the changes in serum Cu levels in patients with psoriasis. Of these, seven studies reported that serum Cu levels were significantly increased in patients with psoriasis. In contrast, five studies reported that there was no statistically significant difference in serum Cu levels between patients with psoriasis and healthy controls. The heterogeneity test results indicated high heterogeneity of the included studies (I^2^ = 95%; Tau^2^ = 1.04; Chi-square = 230.32; df = 11; *P* \< 0.00001). Thus, we used a random-effects model for pooled analysis of the results. According to the pooled analysis, we determined that compared with those of healthy controls, serum Cu levels were significantly increased in patients with psoriasis (Z = 4.02, *P* \< 0.0001; SMD, 1.23; 95% CI, 0.63 to 1.82; [Figure 2](#F2){ref-type="fig"}).

![Random-effects meta-analysis of studies that examined serum Cu levels](IJD-64-224-g002){#F2}

### Changes in serum Zn levels in patients with psoriasis {#sec3-7}

Twelve studies analyzed changes in serum Zn levels in patients with psoriasis. Among these, eight studies concluded that serum Zn levels were significantly decreased in patients with psoriasis compared with those of healthy controls, whereas four references identified no statistically significant differences. Heterogeneity test results indicated that the heterogeneity of the included references was relatively high (I^2^ = 98%; Tau^2^ = 2.45; Chi-square = 626.74; df = 11; *P* \< 0.00001). Therefore, a random-effects model was selected for pooled estimate. Pooled analysis revealed that serum Zn levels were significantly lower in patients with psoriasis than those in healthy controls (Z = 2.95, *P* \< 0.0001; SMD, −1.35; 95% CI, −2.25 to -0.45; [Figure 3](#F3){ref-type="fig"}).

![Random-effects meta-analysis of studies that examined serum Zn levels](IJD-64-224-g003){#F3}

### Influence analysis {#sec3-8}

The influence analysis results are displayed in [Figure 4](#F4){ref-type="fig"}. After rejecting the studies indicated with strikethrough lines, the combined effect value of the remaining studies was calculated. The influence analysis indicated that no single study produced obvious effects on the total combined effect value.

![Influence analysis of serum Cu (a) and serum Zn (b) levels from 12 articles](IJD-64-224-g004){#F4}

### Publication bias {#sec3-9}

The possible existence of publication bias was assessed using the Begg and Egger tests. The results indicated that there was no obvious publication bias regarding the pooled analysis of serum Cu and Zn levels in patients with psoriasis (Begg *P* = 0.304, Egger *P* = 0.258; Begg *P* = 0.732, Egger *P* = 0.738, respectively).

Discussion {#sec1-4}
==========

Zn is one of the most important trace elements and plays an important role in protein synthesis, DNA and RNA repair, biofilm stability, enzyme activity regulation, and free radical scavenging activity.\[[@ref8][@ref14]\] Studies have determined that Zn impacts psoriasis by regulating keratinization in epithelium, immune function, and enzyme functions.\[[@ref23]\] However, the relationship between serum Zn levels and psoriasis remains controversial. Butnaru *et al.*\[[@ref24]\] reported that serum Zn levels were increased in patients with psoriasis. Ala *et al.*,\[[@ref14]\] Cao *et al.*,\[[@ref21]\] Halevy *et al.*,\[[@ref16]\] and Tasaki *et al.*\[[@ref13]\] concluded that no significant changes in serum Zn levels existed in patients with psoriasis compared with those of healthy controls. However, other studies determined that serum Zn levels were lower in patients with psoriasis.\[[@ref5][@ref9][@ref11][@ref12][@ref15][@ref17][@ref18][@ref20]\]

In this meta-analysis, we included 12 references that analyzed changes in serum Zn levels in patients with psoriasis. We determined that compared with healthy controls, serum Zn levels were significantly lower in patients with psoriasis. The mean value for serum Zn levels in patients with psoriasis and the correlation with gender, severity, duration, and disease stage are displayed in [Table 2](#T2){ref-type="table"}. There were no differences in serum Zn levels between male and female patients with psoriasis.\[[@ref9]\] As psoriasis worsened, serum Zn levels gradually decreased,\[[@ref9][@ref15]\] indicating that levels may be closely associated with psoriasis outcome. Yan *et al.*\[[@ref17]\] demonstrated that serum Zn levels were negatively correlated with psoriasis duration, but Cao *et al.*\[[@ref21]\] and Lei *et al.*\[[@ref20]\] reached opposite conclusions.

###### 

Serum levels of Zn in different types of psoriasis

  Study   Gender      Severity    Stage         Disease period                                                                      
  ------- ----------- ----------- ------------- ---------------- ------------- ----------- -------------- ------------ ------------ --------------------
  14      0.73±0.16   0.71±0.15                                                                                                     
  15      4.32±1.70   4.04±1.73   5.8±1.67      4.42±0.97        3.54±0.82     2.24±0.51                                            
  9                               0.008±0.002                    0.007±0.001                                                        
  20                                                                                       116.91±16.66   97.31±9.17   88.54±7.93   
  21                                                                                       1.35±0.82      1.03±0.60    0.98±0.57    
  11                                                                                       0.84±0.19      0.97±0.15                 
  17                                                                                                                                *Y*=11.5750.342*X*

Serum levels of Zn is presented in the form of mean ± SD

The mechanism underlying the reduction in Zn levels in patients with psoriasis is not fully understood. Zn is an essential component of DNA and RNA polymerases. The excessive keratinocyte proliferation associated with psoriasis consumes large amounts of Zn, which may lead to a reduction in serum Zn levels.\[[@ref5]\] In patients with severe psoriasis, skin lesions become more serious, which makes keratinocytes even more exfoliate. Thus, the low serum Zn levels were more obvious in patients with severe psoriasis than those in patients with mild psoriasis. With prolonged disease duration, Zn consumption is increased. Therefore, serum Zn levels are negatively correlated with disease duration.\[[@ref20]\] However, the results of studies investigating the relationship between Zn levels and the different stages of psoriasis were inconsistent. In addition, only three references were included, which was insufficient to perform a pooled analysis of changing serum Zn level trends. Additional studies are required to clarify this relationship.

Zn is an essential component of antioxidant-related enzymes, such as superoxide dismutase (SOD), and plays an important role in free radical scavenging and lipid peroxidation.\[[@ref8]\] In addition, Zn is an essential element for maintenance of T cells and other immune cells and functions and plays a role in T cell differentiation, maturation, activation, and signal transduction.\[[@ref11]\] Low serum Zn levels lead to decreased antioxidant-related enzyme activities and cellular immune dysfunction. Patients with low serum Zn levels are more susceptible to viruses and bacterial infections, which can cause abnormal changes in the skin and trigger psoriasis. Therefore, oral Zn supplementation may be an adjuvant therapy for psoriasis. However, one study reported that oral Zn supplementation was not effective in reducing the psoriasis area and severity index.\[[@ref25]\]

This meta-analysis demonstrated that, in contrast to the low serum Zn levels, serum Cu levels were increased in patients with psoriasis. Cu, another trace element and an important component of enzymes and other functional proteins, has critical biological functions.\[[@ref26]\] With the rapid proliferation of epidermal cells, it is reasonable to expect that Cu consumption should be increased and serum Cu levels should be decreased. However, consistent with previous studies,\[[@ref5][@ref9][@ref12][@ref13][@ref14][@ref22]\] we observed that serum Cu levels were higher in patients with psoriasis than in healthy controls. Furthermore, serum Cu levels were further elevated in patients with psoriasis that was more serious, more active, and with a longer duration \[[Table 3](#T3){ref-type="table"}\]. Serum Cu is primarily bound to ceruloplasmin in serum.\[[@ref5][@ref14]\] Ceruloplasmin is a multifunctional enzyme that maintains Cu homeostasis. It was recently determined that ceruloplasmin is an acute inflammatory reaction protein that has the ability to scavenge free radicals, thereby removing free radicals released into the extracellular matrix and protecting cell lipid membranes from free radical damage.\[[@ref10][@ref27]\] Psoriasis is a chronic inflammatory skin disease with a relatively higher level of oxidative stress. As a result, ceruloplasmin activity increased.\[[@ref5]\] Serum Cu levels are positively correlated with ceruloplasmin levels.\[[@ref10]\] Thus, the high serum Cu levels observed in patients with psoriasis might be caused by the increased ceruloplasmin levels.

###### 

Serum levels of Cu in different types of psoriasis

  Study   Gender      Severity    Stage         Disease duration                                                                                            
  ------- ----------- ----------- ------------- ------------------ ------------ -------------- ------------- ----------- ------------- -------------------- --------------
  14      0.73±0.15   0.68±0.01                                                                                                                             
  19                              1.24±0.22     1.48±0.40          1.51±0.3                                                                                 
  9                               0.022±0.008                      0.02±0.006                                                                               
  21                                                                            0.60±0.41      0.40±0.19     0.42±0.18                                      
  10                                                                            1097.6±228.7   992.4±189.3               986.8±213.3   1057.8±244.9         1082.9±240.2
  17                                                                                                                                   *Y*=1.508+0.403*X*   

Serum levels of Cu is presented in the form of mean ± SD

A publication bias analysis was performed on studies that reported Cu and Zn serum levels. We demonstrated that there was no significant publication bias. However, heterogeneity test results indicated greater homogeneity among the included studies. Therefore, we performed an influence analysis and determined that the exclusion of any single article did not affect the overall results, indicating that the results were reliable.

We first assessed changes in serum Cu and Zn using evidence-based medicine. We determined that serum Zn levels were reduced, and serum Cu levels were elevated in patients with psoriasis. However, the role of serum Cu and Zn in the pathogenesis and development of psoriasis and the exact mechanism underlying this phenomenon remains unclear and requires further investigation. Furthermore, the therapeutic value of Zn supplementation needs to be confirmed in clinical studies.
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